SRGAP3-RAF1 and QKI-RAF1 constructs were synthesized as Gateway compatible entry clones. Full-length RAF1, QKI and SRGAP3 were purchased as gateway entry clones from PlasmID/Dana-Farber/Harvard Cancer Center DNA Resource Core. Sub-cloning was done to integrate SRGAP3-RAF1, QKI-RAF1, full-length QKI, RAF1 and SRGAP3 into Gateway-compatible N-MYC-tagged pMXs-Puro Retroviral Vector (Cell Biolabs). NIH3T3 and early-passage PMAs were transduced using infection protocol previously described18 (link). Gateway destination vectors with either an N-terminal MYC or FLAG tag (Invitrogen) were generated for all constructs. Anti-MYC antibody (Invitrogen R951-25, 1:5000) and anti-FLAG antibody (Sigma A8592, 1:10,000) were used to detect tagged-proteins along with anti-CRAF antibody (Cell Signaling #9422).
QKI-RAF1 dimerization mutants were generated by PCR-based site-directed mutagenesis of MYC- and FLAG-tagged constructs. RAFR401H dimerization mutants35 (link), 36 (link) in QKI-RAF1 were generated using primers: Forward CGCAAAACACACCATGTGAACA and Reverse CAGAACAGCCACCTCATTCCT. QKIE48G dimerization mutants31 (link) in QKI-RAF1 were generated using primers: Forward CTGGACGAAGGAATTAGCAGAG and Reverse CAGCCGCTCGAGGTGGTT.